Terumo Corporation - ADR
TRUMY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q4 2024
May 16, 2024 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
231.7% upsideUndervalued by 231.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.65 Billion |
|---|---|
| Enterprise Value | $120.38 Billion |
| Dividend Yield | $0.17 (1.35%) |
| Earnings per Share | $97.47 |
| Beta | 0.21 |
| Outstanding Shares | 1,475,437,000 |
Return
| Return on Equity | 6.42% |
|---|---|
| Return on Assets | 4.40% |
| Return on Invested Capital | 7.86% |
Valuation & Multiples
| P/E Ratio | 24.15 |
|---|---|
| PEG | 52.17 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 0.14 |
| Enterprise Value to EBIT | 0.86 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 3.17 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▲ 0.00% |
|---|---|
| Total Invested | $579,196▲ 13.78% |
| Investors Holding | 7▼ 3.00% |
ESG Score
No data
About Terumo Corporation
CEO: Shinjiro Sato Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending, notably influencing Medicare pricing which is a major factor in revenue for medical device companies, and impacts corporate valuations through tax policy.
This committee allocates federal spending, directly determining the precise cash flow for defense programs, healthcare initiatives (VA, NIH), and other projects that purchase or fund medical devices.
This committee directly regulates the FDA, which is critical for medical device approvals, and influences NIH funding for research, making it highly relevant to Terumo's core business.
This committee oversees the Department of Defense and authorizes the NDAA, which includes funding for military healthcare and medical technologies, directly impacting potential sales for medical device manufacturers.
This committee's funding decisions directly impact the Department of Veterans Affairs, which is a significant purchaser of medical devices and supplies from manufacturers like Terumo.